Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Strategy

Eastern European Results Roundup: Grindeks, Alkaloid, Olainfarm, Podravka, Sopharma

Several Eastern European generics companies achieved sales growth in 2018. Looking ahead, Grindeks plans to strengthen its presence in Russia and other CIS countries, Alkaloid is set to continue investing in production facilities and technologies, while Olainfarm looks to upgrade its product dossiers.

Europe Companies

Accord Agrees Leuprolide Deal as Part of Differentiation Strategy

Accord is furthering its push into added-value medicines by entering into a licensing agreement for Foresee’s injectable suspension leuprolide injectable.
Value-Added Medicines Deals

Zentiva Set To Acquire Romania's Solacium

Zentiva has signed its first acquisition after it was carved out from Sanofi last year to become an independent company, entering into a shared purchase agreement with Siyiara to acquire Romania-based food supplement and OTC medicines producer Solacium.

Romania M & A

FDA Approves Pfizer's Trastuzumab Biosimilar

Pfizer’s approval for trastuzumab in the US marks the fourth FDA nod for a biosimilar rival to Genentech’s Herceptin original. However, while two of those biosimilar sponsors continue to be engaged in patent litigation with the originator, Pfizer and Mylan have both struck settlement deals.

Biosimilars Regulation

Amneal Targets Up to 50 Launches, But Fears Diminishing Returns

Amneal has a solid roster of generics lined up for introduction in the US this year; but challenging market dynamics are forcing the company to reassess the commercial potential of these launches.
Launches Strategy

Celltrion’s Subcutaneous Infliximab Shows Promise

Data revealed by Korea’s Celltrion demonstrates that the firm’s subcutaneous infliximab is comparable to the intravenous formulation, with a study showing that auto-injection is a viable administrative method.

Biosimilars Strategy
See All